- Home
- PHUN vs IMMX Comparison
PHUN vs IMMX Comparison
Compare PHUN & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- IMMX
- Stock Information
- Founded
- PHUN 2009
- IMMX 2014
- Country
- PHUN United States
- IMMX United States
- Employees
- PHUN N/A
- IMMX N/A
- Industry
- PHUN EDP Services
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- PHUN Technology
- IMMX Health Care
- Exchange
- PHUN Nasdaq
- IMMX Nasdaq
- Market Cap
- PHUN 50.8M
- IMMX 50.1M
- IPO Year
- PHUN N/A
- IMMX 2021
- Fundamental
- Price
- PHUN $3.03
- IMMX $2.10
- Analyst Decision
- PHUN Buy
- IMMX Strong Buy
- Analyst Count
- PHUN 2
- IMMX 1
- Target Price
- PHUN $7.50
- IMMX $7.00
- AVG Volume (30 Days)
- PHUN 148.7K
- IMMX 57.8K
- Earning Date
- PHUN 05-16-2025
- IMMX 05-20-2025
- Dividend Yield
- PHUN N/A
- IMMX N/A
- EPS Growth
- PHUN N/A
- IMMX N/A
- EPS
- PHUN N/A
- IMMX N/A
- Revenue
- PHUN $3,189,000.00
- IMMX N/A
- Revenue This Year
- PHUN $10.47
- IMMX N/A
- Revenue Next Year
- PHUN $55.58
- IMMX N/A
- P/E Ratio
- PHUN N/A
- IMMX N/A
- Revenue Growth
- PHUN N/A
- IMMX N/A
- 52 Week Low
- PHUN $2.22
- IMMX $1.26
- 52 Week High
- PHUN $14.60
- IMMX $2.71
- Technical
- Relative Strength Index (RSI)
- PHUN 58.78
- IMMX 63.96
- Support Level
- PHUN $2.81
- IMMX $1.92
- Resistance Level
- PHUN $3.07
- IMMX $2.25
- Average True Range (ATR)
- PHUN 0.14
- IMMX 0.16
- MACD
- PHUN 0.03
- IMMX 0.03
- Stochastic Oscillator
- PHUN 96.41
- IMMX 73.24
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.